Net cash used in operating and investing activities was $37.4 million in the first quarter; quarter-end cash and restricted cash position was $544.3 millionAdvanced PRX012, a potential best-in-class, subcutaneous
DUBLIN, Ireland, April 28, 2022 (GLOBE NEWSWIRE) Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein